Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04696029 · ClinicalTrials.gov registry record · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
A Phase 2 study of Medulloblastoma, sponsored by Giselle Sholler.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 20
- Study locations
NCT04696029 is a Phase 2 study of Medulloblastoma that is actively recruiting participants, run by Giselle Sholler. The registered enrollment target is 118 participants, below the 137-participant average among 29 other Medulloblastoma trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04696029, a Phase 2 study of Medulloblastoma, is actively recruiting participants, sponsored by Giselle Sholler.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 20
- Study locations
Study Summary
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Conditions Studied
Interventions
- DRUG Difluoromethylornithine
Study Locations (20)
Florida
- Nicklaus Children's Hospital - Miami
- Arnold Palmer Hospital for Children - Orlando
- All Children's Hospital Johns Hopkins Medicine - St. Petersburg
- St. Joseph's Children's Hospital - Tampa
California
- UCSF Benioff Children's Hospital Oakland - Oakland
- Rady Children's Hospital - San Diego
- Stanford University - Stanford
Kentucky
- Kentucky Children's Hospital - Lexington
- Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine - Louisville
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
- Cardinal Glennon Children's Medical Center - St Louis
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Hospital - Hartford
Hawaii
- Kapiolani Medical Center for Women and Children - Honolulu
Illinois
- Advocate Aurora Research Institute - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2029-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04696029
The ClinicalTrials.gov registry entry for NCT04696029 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 29 other Medulloblastoma trials with a reported enrollment target (14% lower). The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medulloblastoma appearing as the primary indexed condition, and to 1 intervention - of which Difluoromethylornithine is the first listed.
NCT04696029 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04696029 about?
NCT04696029 is a clinical study titled "DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma". Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
What is the current status of trial NCT04696029?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2021-03-29. Estimated completion is 2029-03.
What conditions does trial NCT04696029 study?
This clinical trial studies the following conditions: Medulloblastoma.
What interventions are being tested in trial NCT04696029?
The interventions under investigation include: Difluoromethylornithine (DRUG).
Who is sponsoring clinical trial NCT04696029?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04696029 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
Digoxin Medulloblastoma Study
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
-
Methionine PET/CT Studies In Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.